Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 26, Issue 4, Pages 171-180
http://dx.doi.org/10.3233/DMA-2009-0628

Metastatic Breast Cancer Survival according to HER2 and Topo2a Gene Status

N. Todorović-Raković,1 Z. Nešković-Konstantinović,2 and D. Nikolić-Vukosavljević1

1Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
2Department of Clinical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

Received 19 August 2009; Accepted 19 August 2009

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [8 citations]

The following is the list of published articles that have cited the current article.

  • A. F. Munro, J. M. S. Bartlett, and D. A. Cameron, “Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge,” Oncogene, vol. 29, no. 38, pp. 5231–5240, 2010. View at Publisher · View at Google Scholar
  • Yali Lu, Weidong Han, and Po Zhao, “Clinicopathological significance and prognostic value of leukemia-related protein 16 expression in invasive ductal breast carcinoma,” Cancer Science, vol. 101, no. 10, pp. 2262–2268, 2010. View at Publisher · View at Google Scholar
  • Hui Meng, Wencai Li, Li Xu, Renyin Chen, and Lina Xu, “Correlations of TOP2A gene aberrations and expression of topoisomerase IIa protein and TOP2A mRNA expression in primary breast cancer: A retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry,” Pathology International, vol. 62, no. 6, pp. 391–399, 2012. View at Publisher · View at Google Scholar
  • Dragica Nikolic-Vukosavljevic, Natasa Todorovic-Rakovic, and Zora Neskovic-Konstantinovic, “C-myc as a predictive marker for chemotherapy in metastatic breast cancer,” Clinical and Experimental Medicine, vol. 12, no. 4, pp. 217–223, 2012. View at Publisher · View at Google Scholar
  • Marko Buta, Radan Džodić, Igor Đurišić, Ivan Marković, Tijana Vujasinović, Milan Markićević, and Dragica Nikolić-Vukosavljević, “Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up,” Tumor Biology, 2015. View at Publisher · View at Google Scholar
  • Graf, Brucker, Rava, Keilmann, Wallwiener, Fasching, Wallwiener, Simoes, Wilicen, Walter, Hartkopf, and Taran, “Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills,” Geburtshilfe und Frauenheilkunde, vol. 76, no. 5, pp. 535–541, 2016. View at Publisher · View at Google Scholar
  • Olfat Gamil Shaker, and Hebatullah Samy Helmy, “Circulating bone related markers and YKL-40 versus HER2 and TOPO2a in bone metastatic and non-metastatic breast cancer: diagnostic implications,” Clinical Breast Cancer, 2017. View at Publisher · View at Google Scholar
  • Ali Al-Khafaji, Mohammed Alqanbar, Manal Habib, Sahira Ali, and Rasha Neama, “Assessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma,” Indian Journal of Pathology and Microbiology, vol. 60, no. 4, pp. 475–480, 2017. View at Publisher · View at Google Scholar